Table 1. Baseline Characteristics According to eGFR Change 1 Month After TAVR.
| Characteristic | No. (%)a | P value | ||
|---|---|---|---|---|
| Stable eGFR (n = 332) | eGFR improvement (n = 329) | eGFR deterioration (n = 233) | ||
| Demographic characteristics and comorbidities | ||||
| Age, mean (SD), y | 82.1 (6.6) | 81.9 (7.6) | 82.5 (7.3) | .58 |
| BMI, mean (SD) | 27.8 (5.0) | 28.2 (5.4) | 27.8 (4.9) | .54 |
| Women | 166 (50.0) | 177 (53.8) | 109 (46.8) | .25 |
| Men | 166 (50.0) | 145 (44.1) | 124 (53.2) | |
| NYHA class III/IV | 253 (76.1) | 252 (76.5) | 191 (82.0) | .19 |
| Previous PCI | 115 (34.5) | 116 (35.3) | 81 (34.7) | .98 |
| Previous MI | 48 (14.6) | 41 (12.6) | 20 (8.7) | .15 |
| Frailtyb | 43 (12.8) | 47 (14.3) | 32 (13.7) | .84 |
| AF | 63 (19.0) | 63 (19.0) | 50 (21.5) | .74 |
| Previous pacemaker | 26 (7.8) | 27 (8.2) | 21 (9.0) | .88 |
| COPD | 46 (14.0) | 54 (16.5) | 49 (21.1) | .08 |
| Diabetes | 143 (43.1) | 127 (38.7) | 89 (38.2) | .40 |
| Hypertension | 312 (93.9) | 304 (92.4) | 217 (93.1) | .74 |
| STS score, mean (SD), % | 4.7 (3.7) | 5.1 (3.9) | 5.8 (4.5) | .004 |
| Laboratory results | ||||
| Hb, mean (SD), g/dLc | 12.1 (1.7) | 11.7 (1.7) | 11.9 (2.0) | .31 |
| eGFR, mean (SD), mL/min/1.73 m2 | 69.0 (22.6) | 57.1 (19.7) | 68.9 (28.7) | .007 |
| eGFR <60 mL/min/1.73 m2, % | 116 (34.9) | 156 (47.5) | 91 (39.1) | .006 |
| Echocardiographic parameters, mean (SD) | ||||
| AVG peak, mm Hg | 76.2 (21.9) | 76.0 (24.1) | 76.5 (22.2) | .97 |
| AVG mean, mm Hg | 47.8 (15.5) | 48.0 (16.6) | 48.5 (15.2) | .88 |
| AVA, cm2 | 0.67 (0.18) | 0.66 (0.18) | 0.67 (0.18) | .70 |
| LVEF, % | 56.1 (8.7) | 56.6 (8.1) | 55.7 (9.4) | .47 |
| Procedural characteristics | ||||
| Contrast, mean (SD), mL | 151.9 (56.1) | 148.5 (61.9) | 164.1 (70.4) | .02 |
| Contrast to eGFR ratio, mean (SD) | 2.5 (1.8) | 3.1 (3.6) | 3.3 (3.8) | .01 |
| Contrast to eGFR ratio >3.5 | 53 (15.8) | 75 (22.7) | 53 (22.8) | .07 |
| Self-expandable valve | 244 (73.5) | 252 (76.6) | 169 (72.5) | .49 |
| Year of procedure | ||||
| 2008-2012 | 64 (19.3) | 63 (19.2) | 55 (23.5) | .61 |
| 2013-2016 | 134 (40.4) | 124 (37.8) | 90 (38.7) | |
| 2017-2019 | 133 (40.3) | 141 (43.0) | 88 (37.8) | |
| Postprocedural data | ||||
| AKI at discharge | 14 (4.3) | 9 (2.8) | 36 (15.6) | .005 |
| AKI 48 h after TAVR | 23 (7.0) | 20 (6.2) | 57 (24.6) | <.001 |
| Length of admission, median, d | 2 (2-3) | 2 (2-3) | 4 (3-6) | .003 |
Abbreviations: AF, atrial fibrillation; AKI, acute kidney injury; AVA, aortic valve area; AVG, aortic valve gradient; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement.
Values are presented as No. (%) unless otherwise specified.
According to the Rockwood Clinical Frailty Scale, range 0-1, with higher values representing more severe frailty.
To convert g/dL to g/L, multiply by 10.